A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Seraprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ginkgo Pharma
Most Recent Events
- 24 Jan 2021 Primary endpoint of Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment SVR12 has been met, according to results published in the Journal of Gastroenterology and Hepatology.
- 24 Jan 2021 Results published in the Journal of Gastroenterology and Hepatology
- 29 Aug 2020 Status changed from active, no longer recruiting to completed.